An interventional study of Exergaming in Sedentary Lifestyle, sponsored by Norwegian University of Science and Technology. Completed at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-11.
Sponsored by Norwegian University of Science and Technology · Not applicable, Interventional, and Prevention
The purpose of this project is to assess if playing a newly developed videogame that require physical activity (e.g. exergame) can lead to health benefits. The project will include 50 adult participants that are not particularly physically active. They will be randomized into two groups where one group will be given free access to the exergame for 6 months. The physical fitness (maximal oxygen consumption), blood markers of cardiometabolic health and body composition of the subjects will be tested before, mid-ways and after the intervention period. Also, the participants gaming frequency will be registered throughout the 6-month period. Aim of this study is to investigate if access to this game can provide health benefits for individuals who are not motivated to take part in regular physical activity.
Norwegian University of Science and Technology is the lead sponsor of 487 studies on the registry; 52 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
free access to the exergame PedalTanks
Behavioral: Exergaming
recommended to continue with their normal daily routine
free access to the exergame PedalTanks during 6 months
Also known as: PlayPulse, PedalTanks
VO2max (Maximal Aerobic Capacity)
Time frame: 3 months
VO2max (Maximal Aerobic Capacity)
Time frame: 6 months
Daily average energy expenditure
Measured by activity monitors (SenseWear Armband) which participants will wear for one week at start of intervention period, 3-months and 6-months.
Time frame: 3 and 6 months
Daily average number of steps
Measured by activity monitors (SenseWear Armband) which participants will wear for one week at start of intervention period, 3-months and 6-months.
Time frame: 3 and 6 months
Daily time in sedentary activity (< 3.0 metabolic equivalents = METs)
Measured by activity monitors (SenseWear Armband) which participants will wear for one week at start of intervention period, 3-months and 6-months.
Time frame: 3 and 6 months
Daily time in moderate intensity activity (3.0-6.0 metabolic equivalents = METs)
Measured by activity monitors (SenseWear Armband) which participants will wear for one week at start of intervention period, 3-months and 6-months.
Time frame: 3 and 6 months
Daily time in vigorous intensity activity (6.0-9.0 metabolic equivalents = METs)
Measured by activity monitors (SenseWear Armband) which participants will wear for one week at start of intervention period, 3-months and 6-months.
Time frame: 3 and 6 months
Daily time in very vigorous intensity activity (>9.0 metabolic equivalents = METs)
Measured by activity monitors (SenseWear Armband) which participants will wear for one week at start of intervention period, 3-months and 6-months.
Time frame: 3 and 6 months
Daily average total physical activity duration
Measured by activity monitors (SenseWear Armband) which participants will wear for one week at start of intervention period, 3-months and 6-months.
Time frame: 3 and 6 months
Bioelectrical impedance
Body composition assessed using bioelectrical impedance analysis (InBody 720)
Time frame: 3 and 6 months
Blood Pressure
Time frame: 3 and 6 months
Fasting circulating glucose, as blood marker of cardiometabolic health
Time frame: 6 months
Lipid profile, as blood marker of cardiometabolic health
Time frame: 6 months
Circulating insulin concentration, as blood marker of cardiometabolic health
Time frame: 6 months
glucose response to a 2 hour glucose tolerance test, as blood marker of cardiometabolic health
Time frame: 6 months
Plan to share: Undecided
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Norwegian University of Science and Technology